|
Dec 21
|
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-CFB for Complement Mediated Kidney Disease
|
|
Dec 20
|
Arrowhead Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
|
|
Dec 5
|
ARWR: Updates on Plozasiran and Zodasiran at AHA 2023…
|
|
Dec 1
|
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q4 2023 Earnings Call Transcript
|
|
Nov 30
|
Q4 2023 Arrowhead Pharmaceuticals Inc Earnings Call
|
|
Nov 29
|
Arrowhead Pharmaceuticals Inc Reports Fiscal 2023 Year-End Results
|
|
Nov 29
|
Arrowhead Pharmaceuticals Reports Fiscal 2023 Year End Results
|
|
Nov 28
|
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-DM1 for Type 1 Myotonic Dystrophy
|
|
Nov 8
|
Great week for Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) institutional investors after losing 17% over the previous year
|
|
Nov 6
|
Arrowhead Pharmaceuticals to Participate in Jefferies London Healthcare Conference
|
|
Nov 2
|
Arrowhead Pharmaceuticals to Present New Phase 2 Clinical Data on Cardiometabolic Pipeline at AHA 2023
|
|
Sep 11
|
Arrowhead Presents Data on Pulmonary Pipeline at ERS 2023
|
|
Sep 9
|
10 Biotech Stocks with Biggest Upside
|
|
Sep 7
|
Is Arrowhead Pharmaceuticals (ARWR) Too Good to Be True? A Comprehensive Analysis of a ...
|
|
Aug 13
|
Swelling losses haven't held back gains for Arrowhead Pharmaceuticals (NASDAQ:ARWR) shareholders since they're up 99% over 5 years
|
|
Aug 10
|
ARWR: Enrollment Complete in PALISADE Phase 3 Trial of ARO-APOC3 in FCS...
|
|
Aug 8
|
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q3 2023 Earnings Call Transcript
|
|
Aug 8
|
Q3 2023 Arrowhead Pharmaceuticals Inc Earnings Call
|
|
Aug 8
|
15 Worst Performing Biotech Stocks in 2023
|
|
Aug 7
|
Arrowhead Pharmaceuticals Reports Fiscal 2023 Third Quarter Results
|